Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis

Abstract

Teclistamab, BCMA bispecific antibody (BsAb), was approved based upon the MajesTEC-1 study [1] with an overall response rate (ORR) of 63% and a median progression-free survival (PFS) of 11.3 months. In MajesTEC-1, the median age was 64 years, and patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥ 2 were excluded, suggesting that the vast majority of patients were fit. This has lead to a paucity of data both in clinical trials as well as in the real-world regarding the outcomes of older adults treated with BsAbs. We performed a retrospective analysis to understand the outcomes of older adults (age ≥ 70) including frail patients treated in the real-world with teclistamab.

This is was an multicenter retrospective study of patients with relapsed and/or refractory MM enrolled in the International Myeloma Foundation (IMF) immunotherapy database and treated with teclistamab at 7 academic centers across 5 countries between May 2022-Dec 2023. This study received approval from the Institutional Review Boards of the respective participating institutions and inidivdual patients were consented in accordance. Frailty categorization was done using the simplified frailty index and patients categorized as fit (score 0-1) or frail (≥ score 2) [2].